Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

HµrelStaticDog™, Hµrel Corporation’s In Vitro Cell Culture of Canine (Dog) Liver Cells, to be Presented at Toxicology Conference

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Data highlight benefits of new tool for predicting drug toxicity in humans before clinical trials begin - important milestone in drug development evolution.

Hurel Corporation announced that the results of toxicological evaluations performed on HµrelStaticDog™, Hurel’s new, patent-pending method of culturing actual liver cells from the canine (dog) species, will be highlighted as a part of UCB’s keynote overview of the current state of the art of in vitro models to use in early toxicology assessment to detect human hepatotoxic drugs.  The UCB presentation will take place at ADME and Predictive Toxicology 2013, the toxicology symposium to be held in Barcelona, Spain on April 11th at 2:15PM.

The study results derived from HµrelStaticDog™ represent a culmination of a multi-year collaboration between UCB and Hurel under which this new pre-clinical analytic tool was developed.  UCB funded the development of HurelStaticDog™ and has collaborated with Hurel in its characterization and validation testing.

Dr. Leslie Z. Benet, Professor of Bioengineering  and Therapeutic Sciences at the University of California, San Francisco and Head of Hurel’s Scientific Advisory Board, said in connection with the upcoming presentation: “The HµrelStaticDog™ pre-clinical tool represents an important milestone in the evolution of the drug development process, for two reasons.  First, as the R&D collaboration data that will be presented in Barcelona shows, HµrelStaticDog™ is a powerful new in vitro tool for predicting the potential toxicity of drugs in humans well before the clinical trial stage.  And second, because regulatory agencies, such as the FDA and EMA, require testing of every new drug candidate on at least one non-human, “large animal” species such as dog, HµrelStaticDog™ represents a critically important new in vitro, cell-based vehicle for predicting the outcome of animal tests conducted in dogs.  That ability to predict in vivo outcomes in dogs by in vitro testing on HµrelStaticDog™ may be expected to improve the efficient performance of animal testing and thereby help reduce the over-all number of animal tests performed, while also contributing to a reduction in the rate of late-stage failures in human clinical trials.”

HµrelStaticDog™ constitutes the first instance of an advanced, high-functioning, in vitro liver cell culture system comprised of actual living cells from the canine species, which is characterized for use in pre-clinical research activities. HµrelStaticDog™ is expected to find application in the evaluation of the safety (i.e., toxicological) risks of prospective drug candidates, as well as of the metabolic and other pharmacokinetic properties of those drug candidates.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Optivia and Hurel Form Technology and Marketing Alliance
Firms partner to improve understanding of in vitro/in vivo correlation for transporter-mediated hepatic clearance, drug-drug interactions, and drug-induced liver injury.
Thursday, April 30, 2015
Hurel® Corporation Completes Investment from Johnston Associates
Biotech investment veteran Robert F. Johnston joins Hurel investor group.
Wednesday, October 08, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos